SGLT2 inhibitors, such as EMPA, protect the heart in T2DM by restoring autophagy through the activation of SIRT1/AMPK and suppression of the Akt/mTOR signaling pathway [90]. The gene discussed is SIRT1; the disease is type 2 diabetes mellitus.